Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28536955
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Pharmacoeconomics
2017 ; 35
(9
): 859-866
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of
Medicines: Are We Ready Yet?
#MMPMID28536955
Vass CM
; Payne K
Pharmacoeconomics
2017[Sep]; 35
(9
): 859-866
PMID28536955
show ga
There is emerging interest in the use of discrete choice experiments as a means
of quantifying the perceived balance between benefits and risks (quantitative
benefit-risk assessment) of new healthcare interventions, such as medicines,
under assessment by regulatory agencies. For stated preference data on
benefit-risk assessment to be used in regulatory decision making, the methods to
generate these data must be valid, reliable and capable of producing meaningful
estimates understood by decision makers. Some reporting guidelines exist for
discrete choice experiments, and for related methods such as conjoint analysis.
However, existing guidelines focus on reporting standards, are general in focus
and do not consider the requirements for using discrete choice experiments
specifically for quantifying benefit-risk assessments in the context of
regulatory decision making. This opinion piece outlines the current state of play
in using discrete choice experiments for benefit-risk assessment and proposes key
areas needing to be addressed to demonstrate that discrete choice experiments are
an appropriate and valid stated preference elicitation method in this context.
Methodological research is required to establish: how robust the results of
discrete choice experiments are to formats and methods of risk communication; how
information in the discrete choice experiment can be presented effectually to
respondents; whose preferences should be elicited; the correct underlying utility
function and analytical model; the impact of heterogeneity in preferences; and
the generalisability of the results. We believe these methodological issues
should be addressed, alongside developing a 'reference case', before agencies can
safely and confidently use discrete choice experiments for quantitative
benefit-risk assessment in the context of regulatory decision making for new
medicines and healthcare products.
|*Choice Behavior
[MESH]
|*Decision Making
[MESH]
|Delivery of Health Care/economics/*methods
[MESH]
free
free
free
